http://www.fpnotebook.com/
NefazodoneAka: Serzone
- Mechanism
- Serotonin Antagonist and Reuptake Inhibitor
- Phenylpiperazine related to Trazodone (Desyrel)
- Less Sedation than Trazodone
- Less Orthostasis than Trazodone
- No Priapism
- Background
- Costs: $50 per month
- Indications
- Major Depression
- Consider for severe Refractory Depression Management
- Anxiety Disorder
- Post-Traumatic Stress Disorder (PTSD)
- Major Depression
- Contraindications
- Liver disease
- Concurrent medication use
- Cisapride
- MAO inhibitor
- Triazolam
- Terfenadine
- Astemizole
- Efficacy
- Shown to be as effective as Imipramine
- No comparison trials with SSRIs
- Pharmacokinetics
- Half life: 18 hours
- Steady state in 4-5 days
- Inhibits cytochrome P450 3A4
- Clearance decreased
- Elderly
- Hepatic dysfunction
- Dosing: General
- Start: 100 mg PO qhs for 3 days
- Twice daily dosing (FDA approved dosing, or anxiety)
- Next: 100 mg PO bid for 7 days
- Next: Increase at 1 week intervals to 300 mg PO bid
- Once daily dosing (typical dosing by psychiatrists)
- Next: 200 mg PO qhs for 7 days
- Next: Increase at 1 week intervals upto 600 mg PO qhs
- Maximum: 600 mg per day
- Dosing: Elderly over age 65 years
- Start: 50 mg PO bid
- Next: 50-200 mg PO bid
- Advantages
- Precautions
- Risk of liver failure (one per 250,000)
- Contraindicated in comorbid liver disease
- Patient and physician watch closely for hepatotoxicity
- Consider Liver Function Testing
- Adverse effects (May be intolerable)
- Sedation (limiting adverse effect)
- Some psychiatrists dose only in evening
- Anticholinergic Symptoms increased over SSRIs
- Confusion
- Dry Mouth
- Constipation
- Nausea
- Dizziness
- Blurred vision
- Other Adverse Effects
- Anxiety may occur due to metabolite (mCPP)
- See drug interactions below
- Sedation (limiting adverse effect)
- Drug Interactions
- Stop MAO inhibitor 14 days prior to starting Serzone
- Inhibits Cytochrome P450 system (CYP3A4, CYP2D6)
- Metabolite mCPP cleared by Cytochrome P450-2D6
- Decreased clearance of
- References
- (1995) Med Lett Drugs Ther 37(946):33
- Sundberg (1995) Depression Primary Care, PGM, p. 45-57
nefazodone (C0068485) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C051752 |
| English | nefazodone, NEFAZODONE PREPARATION |
| Spanish | nefazodona |
| Parent Concepts | Antidepressive Agents (C0003289), Triazoles (C0040880), [CN609] ANTIDEPRESSANTS, OTHER (C0973506), Piperazine derivative (C0304303), Selective serotonin re-uptake inhibitor (C0360105), Triazole derivative (C1689939), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) (C1579361) |
| Sources | LNC, MSH, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Serzone (C0591424) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C051752 |
| English | Bristol-Myers brand of nefazodone hydrochloride, Bristol-Myers Squibb brand of nefazodone hydrochloride, Dutonin, Serzone |
| Sources | MSH, MTH, NCI, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |